

## Bangladesh market snapshot

|                                | Last closing |
|--------------------------------|--------------|
| DSEX Index                     | 4,899.65     |
| % change                       | -0.58%       |
| DS30 Index                     | 1,703.33     |
| % change                       | -0.96%       |
| DSES Index                     | 1,112.80     |
| % change                       | -0.75%       |
| Turnover (BDT mn)              | 9,251.14     |
| Turnover (USD mn)              | 110.13       |
| % change                       | 4.97%        |
| Market Capitalization (BDT bn) | 3,980        |
| Market Capitalization (USD bn) | 47.38        |
| % change                       | -0.44%       |

Source: Dhaka Stock Exchange

## International market snapshot

|                              | Last closing |
|------------------------------|--------------|
| Dow Jones Industrial Average | 29,420.92    |
| % change                     | +0.90%       |
| Nikkei 225                   | 25,338.52    |
| % change                     | +1.74%       |
| FTSE 100                     | 6,296.85     |
| % change                     | +1.79%       |

Source: Bloomberg

## Exchange rate

| Currency | BDT    |
|----------|--------|
| USD      | 84.80  |
| EUR      | 100.71 |
| GBP      | 111.59 |
| INR      | 1.15   |

Source: Bangladesh Bank

## Money market

| Date        | Call Money Rate Range (%) | Weighted Average (%) |
|-------------|---------------------------|----------------------|
| 09-Nov-2020 | 1.00-5.25                 | 2.18                 |
| 08-Nov-2020 | 1.00-5.25                 | 2.07                 |

Source: Bangladesh Bank

## Commodities

|                            | Price    | % Change |
|----------------------------|----------|----------|
| Brent Crude (Oil), USD/bbl | 44.03    | +0.96%   |
| Gold Spot, USD/t oz        | 1,882.35 | +0.27%   |
| Cotton, USD/lb             | 72.03    | +0.53%   |

Source: Bloomberg

## Economy

### Businesses fear further losses as second wave looms large

Exporters and local businesses have received a shot in the arm since June on the back of improved economic activity but the fragile recovery could evaporate before taking root if the country is hit with a second wave of the Covid-19. If there are new waves of infections as already seen in some export destinations, the recovery for the exporters would be short-lived. In the same vein, a second wave in Bangladesh could mean a return of containment measures and this may drag down economic activity for a second time in less than eight months.

<https://www.thedailystar.net/business/news/businesses-fear-further-losses-second-wave-looms-large-1992917>

## Bank and NBFI

### Banks' disclosure rules changed

The central bank has amended its instruction, allowing banks to provide their market disclosures within seven working days of finalizing the annual audited financial statements, instead of March or September. Under the amendments, the banks are now instructed to provide required market disclosures in both qualitative and quantitative forms within seven working days of finalizing the annual audited financial statements as per the allowable time limit under Section 40 of Bank Company Act 1991. The banks are now allowed to finalize their annual financial statements within the next two months after ending the calendar or fiscal year in line with the existing Bank Company Act.

<https://today.thefinancialexpress.com.bd/first-page/banks-disclosure-rules-changed-1605031186>

## Capital Market

### BB selects 30 bonds for benchmarking

The Bangladesh Bank (BB) has selected 30 treasury bonds for benchmarking as part of its latest move to develop a secondary market for the government securities. It took the ones, which are frequently traded or auctioned in large volume, out of the total 269 active treasury bonds. The government securities are, in real terms, not market-based ones and the benchmarking will be one-step forward towards developing an effective secondary market for the treasury bonds. Setting up of such benchmark is expected to help the primary dealer (PD) banks to quote in two ways (buy-sell) to the parties concerned.

<https://today.thefinancialexpress.com.bd/first-page/bb-selects-30-bonds-for-benchmarking-1605031130>

## Stock

### ACI declares 90pc dividend despite losses

Advanced Chemical Industries (ACI) Ltd has decided to pay 80 percent cash and 10 percent stock dividends for the year ended on June 30, 2020, despite incurring a loss of Tk18.45 per share

(consolidated). The company has reported consolidated earnings per share (EPS) of Tk 18.45 in the negative, consolidated net asset value (NAV) per share of Tk 137.67 and consolidated net operating cash flow per share (NOCFPS) of Tk 82.79 for the year ended on June 30, 2020 as against Tk 13.51 in negative, Tk 166.95 and Tk 25.67 in negative respectively for the same period of the previous year. However, the ACI's standalone EPS stood at Tk 29.96, NAV per share of Tk 268.79 and NOCFPS of Tk 78.30 for the year ended on June 30, 2020 as against Tk 9.26, Tk 249.64 and Tk 25.44 respectively for the same period of the previous year.

<https://today.thefinancialexpress.com.bd/stock-corporate/aci-declares-90pc-dividend-despite-losses-1605024870>

<https://www.thedailystar.net/business/news/aci-returns-profit-higher-sales-hygiene-products-1992909>

## Disclaimer

### IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UCB Capital Management Ltd. ("UCB"), a company authorized to engage in securities activities in Bangladesh. UCB is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc. ("RBLT"), 40 Wall Street 59th Floor, New York NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UCB. RBLT accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of RBLT and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

### Ownership and Material Conflicts of Interest

RBLT or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. RBLT, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. RBLT is not aware of any material conflict of interest as of the date of this publication.

### Compensation and Investment Banking Activities

RBLT or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

### Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither UCB nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

UCB may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of UCB.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by UCB with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of UCB and UCB accepts no liability whatsoever for the actions of third parties in this respect.

#### **EQUITY RECOMMENDATION STRUCTURE (ABSOLUTE RATINGS)**

We calculate our target price by weighting DCF, DDM, SOTP, asset-based and other relative valuation methods, and applying appropriate premiums/ discounts and/or other relevant adjustments.

Expected absolute returns are calculated as the percentage of difference between our target price and latest close price. Stock recommendations are based on absolute upside (downside) and have a 12-month horizon. Please note that future price fluctuations could lead to a temporary mismatch between upside/downside for a stock and our recommendation.

| Recommendation Type | Holding period (if not otherwise mentioned) | Absolute Return Potential |
|---------------------|---|---------------------------|
| Buy                 | 12 Months                                   | More than +15%            |
| Neutral/ Hold       | 12 Months                                   | Between +15 % and -5 %    |
| Underweight         | 12 Months                                   | Less than -5 %            |

#### **ANALYST CERTIFICATION**

Respective analyst(s) identified in this report certifies, with respect to the companies or securities that the individual analyst(s), that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. The research analyst(s) named on this report are not registered / qualified as research analysts with FINRA.

*It has not been determined in advance whether and in what intervals this document will be updated. Unless otherwise stated current prices refer to the most recent trading day's closing price.*

## Contact Us

### Research Team

|                              |                         |                            |                   |
|------------------------------|-------------------------|----------------------------|-------------------|
| Md. Hasib Reza, CFA          | Head of Research        | hasib.reza@ucb.com.bd      | +880 1755 658 997 |
| Md. Sakib Chowdhury, CFA     | Deputy Head of Research | sakib.chowdhury@ucb.com.bd | +880 1713 205 698 |
| Md. Nazmus Sakib             | Research Associate      | nazmus.sakib@ucb.com.bd    | +880 1701 205 073 |
| Anik Mahmood Ibne Anwar, CFA | Research Associate      | anik.mahmood@ucb.com.bd    | +880 1701 205 074 |
| Shadman Sadique Kamal        | Research Associate      | shadman.kamal@ucb.com.bd   | +880 1701 205 096 |

### Investment Strategist

|                      |                |                       |                   |
|----------------------|----------------|-----------------------|-------------------|
| Syed Adnan Huda, CFA | Vice President | adnan.huda@ucb.com.bd | +880 1730 325 232 |
|----------------------|----------------|-----------------------|-------------------|

### Institutional & Foreign Trade

|                   |                             |                            |                   |
|-------------------|-----------------------------|----------------------------|-------------------|
| Sonchoy Saha, CFA | Head of Institutional Sales | sonchoy.kumer@ucb.com.bd   | +880 1755 615 313 |
| Tahmidur Rahman   | Senior Executive Officer    | rahman.tahmidur@ucb.com.bd | +880 1726 995 520 |

### Office Premises

**Head Office**  
6, Dilkusha C/A  
1st Floor  
Dhaka- 1000  
Bangladesh

**Corporate Office**  
Bulus Center (Level-2)  
Plot-CWS(A)-1, Road No-34  
Gulshan Avenue  
Dhaka- 1212  
Bangladesh

**Extension of Main Office**  
Room 126, DSE Tower Level- 8  
Plot- 46, Road- 21, Nikunja  
Dhaka- 1229  
Bangladesh

**Extension of Main Office**  
NIK Tower, 55 Dilkusha C/A,  
(4th Floor), Dhaka-1000.

**Chattogram Office**  
Muntasir Centre (5th Floor),  
253, Wasa Circle, Dampara  
Khulshi, Chattogram.